What medicine is Venetoclax?

Venetoclax (Venetoclax) is a potent, oral, highly selective small molecule inhibitor of the anti-apoptotic B-cell lymphoma 2 protein that has been approved for treatment in patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (in combination with obinutuzumab) or in patients with relapsed/refractory chronic lymphocytic leukemia (in combination with rituximab). Venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine is also approved in the United States for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults ≥75 years of age or with comorbidities that preclude the use of intensive induction chemotherapy.

Veneclar is being developed by AbbVie and Genentec. Current clinical studies in patients with chronic lymphocytic leukemia or acute myeloid leukemia have reported hematological (such as neutropenia) and non-hematological (such as gastrointestinal disorders and tumor lysis syndrome) adverse events associated with the administration of venetoclat.

The original drug of Venacla is already on the market in China, and can be found in the Category B medical insurance directory. The specification is 100mg*14 tablets and the price per box may be around RMB 5,000. The Turkish version of Venaclaoriginal drug, specifications100mg*112 tablets, sold overseas, costs around RMB 10,000 per box (the price may fluctuate due to exchange rates), which is even more expensive. Cheaper generic drugs are also sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs. The price of a box of 100mg*120 tablets produced by a Bangladeshi pharmaceutical factory is around RMB 4,000 (prices may fluctuate due to exchange rates).